- Cells
- T cells, PBMCs, iPSCs, CD34+
- Cargos
- mRNA, CRISPR RNPs, siRNA, circRNA
Publication text
Ridiculously Simple, Scalable Cell Engineering Started 1st company (SQZ) as MIT ChemE PhD 2015-2016 Diagnosed with cancer, cured after 6 chemo cycles SQZ IPO: +$400M raised and 3 clinical trials RESET: Started Portal and launched Beta product… My Biotech Spinout Journey Cell Permeability is a Massive Challenge for (i) Drug Discovery and (ii) Cell Therapy CRISPR Peptides
Rna
Dna
Portal Solves this Problem with a Simple, Scalable Approach
Mechanical Disruption Intracellular Deliverycells and Cargo
Cells Cargo Critically enabling technology underpinning next gen cell therapy and discovery analytics +10 patent filings to date! Universal Delivery System Cells Engineered Cells Cell Modification Library (non-genetic) Cargo Point of Care Production Goal: The Foundational Platform for Next Gen Cell Therapies Portal’s Growth To Date Products Across Scales Research High Throughput Clinical 50+
$1m
Employees Exceeded 2024 target Revenue Partners Armon Sharei, PhD (CEO): Founder & former CEO of SQZ Biotech. Invention to post-IPO with over $300M in equity financing and a + $1Bn Roche collaboration Alec Barclay (COO): Former COO of T2Biosystems. Sr. R&D leader at Becton Dickinson and Siemens. 5 FDA cleared / commercialized devices, 13 assays, 6 RUO/CE devices Anil Narasimha, PhD (CCO): Former CEO of Mekonos, nano-needles for precision cell delivery company. Raised over $30M in venture funding
Some publications reference SQZ Biotechnologies, a company Dr. Armon Sharei and colleagues previously founded. Portal is the next generation company leveraging Dr. Sharei's platform technology.
# Ridiculously simple, scalable cell engineering
This page is a text version of a Portal Biotechnologies publication. The bibliographic record is labeled in the text so it can be read without the surrounding website.
## Bibliographic record
- Title: Ridiculously simple, scalable cell engineering
- Document type: Presentation
- Year: 2025
- Outlet: Deep Tech Global Summit
- Cells: T cells, PBMCs, iPSCs, CD34+
- Cargos: mRNA, CRISPR RNPs, siRNA, circRNA
- Page URL: https://portal.bio/publications/2025-ridiculously-simple-scalable-cell-engineering--ajkGKREAACoAc91p
- Markdown URL: https://portal.bio/publications/2025-ridiculously-simple-scalable-cell-engineering--ajkGKREAACoAc91p.md
- Original file: https://portal-bio.cdn.prismic.io/portal-bio/aFmbgHfc4bHWioYd_Portal-HelloTomorrowPresentation2025.pdf
## Publication text
Ridiculously Simple, Scalable Cell Engineering Started 1st company (SQZ) as MIT ChemE PhD 2015-2016 Diagnosed with cancer, cured after 6 chemo cycles SQZ IPO: +$400M raised and 3 clinical trials RESET: Started Portal and launched Beta product… My Biotech Spinout Journey Cell Permeability is a Massive Challenge for (i) Drug Discovery and (ii) Cell Therapy CRISPR Peptides
### Rna
### Dna
Portal Solves this Problem with a Simple, Scalable Approach
### Mechanical Disruption Intracellular Deliverycells and Cargo
Cells Cargo Critically enabling technology underpinning next gen cell therapy and discovery analytics +10 patent filings to date! Universal Delivery System Cells Engineered Cells Cell Modification Library (non-genetic) Cargo Point of Care Production Goal: The Foundational Platform for Next Gen Cell Therapies Portal’s Growth To Date Products Across Scales Research High Throughput Clinical 50+
### $1m
Employees Exceeded 2024 target Revenue Partners Armon Sharei, PhD (CEO): Founder & former CEO of SQZ Biotech. Invention to post-IPO with over $300M in equity financing and a + $1Bn Roche collaboration Alec Barclay (COO): Former COO of T2Biosystems. Sr. R&D leader at Becton Dickinson and Siemens. 5 FDA cleared / commercialized devices, 13 assays, 6 RUO/CE devices Anil Narasimha, PhD (CCO): Former CEO of Mekonos, nano-needles for precision cell delivery company. Raised over $30M in venture funding
## Provenance
Some publications reference SQZ Biotechnologies, a company Dr. Armon Sharei and colleagues previously founded. Portal is the next generation company leveraging Dr. Sharei's platform technology.
Back